Severe Mycoplasma pneumoniae infection in a young child: An emerging increase in incidence?
Article Sidebar
Main Article Content
Abstract
-
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
How to Cite
References
1. Tamura A, Matsubara K, Tanaka T, Nigami H, Yura K, Fukaya T. Methylprednisolone pulse therapy for refractory Mycoplasma pneumoniae pneumonia in children. J Infect 2008;57(3):223-228. https://doi.org/10.1016/j.jinf.2008.06.012
2. Lanata MM, Wang H, Everhart K, Moore-Clingenpeel M, Ramilo O, Leber A. Macrolide-resistant Mycoplasma pneumoniae infections in children, Ohio, USA. Emerg Infect Dis 2021;27(6):1588-1597. https://doi.org/10.3201/eid2706.203206
3. Parums DV. Editorial: Outbreaks of post-pandemic childhood pneumonia and the re-emergence of endemic respiratory infections. Med Sci Monit 2023;29:e943312. https://doi.org/10.12659/MSM.9433124. Akashi Y, Hayashi D, Suzuki H, et al. Clinical features and seasonal variations in the prevalence of macrolide-resistant Mycoplasma pneumoniae. J Gen Fam Med 2018;19(6):191-197. https://doi.org/10.1002/jgf2.201
5. Zhao J, Ji X, Wang Y, Wang X. Clinical role of serum interleukin-17A in the prediction of refractory Mycoplasma pneumoniae pneumonia in children. Infect Drug Resist 2020;13:835-843. https://doi.org/10.2147/IDR.S240034
6. Choi YJ, Chung EH, Lee E, et al. Clinical characteristics of macrolide-refractory Mycoplasma pneumoniae pneumonia in Korean children: A multicenter retrospective study. J Clin Med 2022;11(2):306. https://doi.org/10.3390/jcm11020306
7. Kawamata R, Yokoyama K, Sato M, et al. Utility of serum ferritin and lactate dehydrogenase as surrogate markers for steroid therapy for Mycoplasma pneumoniae pneumonia. J Infect Chemother 2015;21(11):783-789. https://doi.org/10.1016/j. jiac.2015.07.009
8. Qiu J, Ge J, Cao L. D-dimer: The risk factor of children’s severe Mycoplasma pneumoniae pneumonia. Front Pediatr 2022;10:828437. https://doi.org/10.3389/ fped.2022.828437
9. LeeKL,LeeCM,YangTL,etal.SevereMycoplasmapneumoniaepneumoniarequiring intensive care in children, 2010-2019. J Formos Med Assoc 2021;120(1 Pt 1):281-291. https://doi.org/10.1016/j.jfma.2020.08.018
10. MorozumiM,TakahashiT,UbukataK.Macrolide-resistantMycoplasmapneumoniae: Characteristics of isolates and clinical aspects of community-acquired pneumonia. J Infect Chemother 2010;16(2):78-86. https://doi.org/10.1007/s10156-009-0021-4
11. Okada T, Morozumi M, Tajima T, et al. Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children. Clin Infect Dis 2012;55(12):1642-1649. https:// doi.org/10.1093/cid/cis784
12. Kimberlin DW, ed., Barnett ED, Lynfield R, Sawyer MH, assoc. eds. Red Book: 2021- 2024 Report of the Committee on Infectious Diseases. 32nd ed. Itasca, Ill.: American Academy of Pediatrics, 2021.
13. Todd SR, Dahlgren FS, Traeger MS, et al. No visible dental staining in children treated with doxycycline for suspected Rocky Mountain spotted fever. J Pediatr 2015;166(5):1246-1251. https://doi.org/10.1016/j.jpeds.2015.02.015
14. Luo Z, Luo J, Liu E, et al. Effects of prednisolone on refractory Mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol 2014;49(4):377-380. https:// doi.org/10.1002/ppul.22752
15. Meyer Sauteur PM, Chalker VJ, Berger C, Nir-Paz R, Beeton ML; ESGMAC and the ESGMAC-MyCOVID study group. Mycoplasma pneumoniae beyond the COVID-19 pandemic: Where is it? Lancet Microbe 2022;3(12):e897. https://doi.org/10.1016/ S2666-5247(22)00190-2